Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Net Income Loss of $3.95 billion for the year ending 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +838.1% in Net Income Loss from 2024 to 2025.
- This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$232.46 million | Q2 2014: -$159.38 million | Q3 2014: -$170.06 million | Q4 2014: -$176.66 million | Q1 2015: -$198.61 million | Q2 2015: -$188.85 million | Q3 2015: -$95.15 million | Q4 2015: -$73.73 million | Q1 2016: -$41.63 million | Q2 2016: -$64.53 million | Q3 2016: -$38.84 million | Q4 2016: $32.95 million | Q1 2017: $247.76 million | Q2 2017: $18.00 million | Q3 2017: -$102.95 million | Q4 2017: $100.68 million | Q1 2018: $210.26 million | Q2 2018: $207.36 million | Q3 2018: $128.75 million | Q4 2018: $1.55 billion | Q1 2019: $268.63 million | Q2 2019: $267.43 million | Q3 2019: $57.52 million | Q4 2019: $583.23 million | Q1 2020: $602.75 million | Q2 2020: $837.27 million | Q3 2020: $667.43 million | Q4 2020: $604.19 million | Q1 2021: $653.10 million | Q2 2021: $67.00 million | Q3 2021: $851.90 million | Q1 2022: $762.10 million | Q2 2022: $810.50 million | Q3 2022: $930.50 million | Q1 2023: $699.80 million | Q2 2023: $915.70 million | Q3 2023: $1.04 billion | Q1 2024: $1.10 billion | Q2 2024: -$3.59 billion | Q3 2024: $1.05 billion | Q1 2025: $646.30 million | Q2 2025: $1.03 billion | Q3 2025: $1.08 billion.
- Over the full 17 years of available data (2009 to 2025), VERTEX PHARMACEUTICALS INC / MA's Net Income Loss has grown by 715.6%.
- Historical annual values: Fiscal year 2025: $3.95 billion | Fiscal year 2024: -$535.60 million | Fiscal year 2023: $3.62 billion | Fiscal year 2022: $3.32 billion | Fiscal year 2021: $2.34 billion | Fiscal year 2020: $2.71 billion | Fiscal year 2019: $1.18 billion | Fiscal year 2018: $2.10 billion | Fiscal year 2017: $263.48 million | Fiscal year 2016: -$112.05 million | Fiscal year 2015: -$556.33 million | Fiscal year 2014: -$738.56 million | Fiscal year 2013: -$445.03 million | Fiscal year 2012: -$107.03 million | Fiscal year 2011: $29.57 million | Fiscal year 2010: -$754.63 million | Fiscal year 2009: -$642.18 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: